To determine the prognostic potential of Sig24 for identifying prostate cancer patients at risk of developing metastases or experiencing PCSM following radical prostatectomy.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Sig24 scores were calculated from previously collected gene expression microarray data from the Cleveland Clinic and Mayo Clinic (I and II). The performance of Sig24 was determined using time-dependent c-index analysis, Cox proportional hazards regression and Kaplan-Meier survival analysis.
Higher Sig24 scores were significantly associated with higher pathologic Gleason scores (GS) in all three cohorts. Analysis of the Mayo Clinic II cohort, which included time to event information, indicated that patients with high Sig24 scores also had an increased risk of developing metastasis (HR: 3.78, 95% CI: 1.96-7.29, p < 0.001) or experiencing PCSM (HR: 6.54, 95% CI: 2.16-19.83, p < 0.001).
The findings of this study demonstrate the applicability of Sig24 for the prognosis of metastasis or PCSM following radical prostatectomy. Future studies investigating the combination of Sig24 with available prognostic tests may provide new approaches to improve risk stratification for patients with prostate cancer. This article is protected by copyright. All rights reserved.
BJU international. 2017 Jan 20 [Epub ahead of print]
Kathryn L Pellegrini, Martin G Sanda, Dattatraya Patil, Qi Long, María Santiago-Jiménez, Mandeep Takhar, Nicholas Erho, Kasra Yousefi, Elai Davicioni, Eric A Klein, Robert B Jenkins, R Jeffrey Karnes, Carlos S Moreno
Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., Winship Cancer Institute, Emory University, Atlanta, GA, USA., GenomeDx Biosciences, Vancouver, BC, Canada., Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA., Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN, USA., Department of Urology, Mayo Clinic, Rochester, MN, USA.